We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MetaMap® Tox - A Novel Technology for Early Safety Enablement in Pharmaceutical Development will be Validated by Industry Consortium
Product News

MetaMap® Tox - A Novel Technology for Early Safety Enablement in Pharmaceutical Development will be Validated by Industry Consortium

MetaMap® Tox - A Novel Technology for Early Safety Enablement in Pharmaceutical Development will be Validated by Industry Consortium
Product News

MetaMap® Tox - A Novel Technology for Early Safety Enablement in Pharmaceutical Development will be Validated by Industry Consortium


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "MetaMap® Tox - A Novel Technology for Early Safety Enablement in Pharmaceutical Development will be Validated by Industry Consortium"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Drug Safety Executive Council (DSEC), an industry membership run by Cambridge Healthtech Associates (CHA), together with Metanomics Health GmbH, a BASF Group company, and leader in offering targeted and non-targeted metabolite profiling to healthcare customers, have announced a new project as part of DSEC's Technology Evaluation Consortium.

The goal of the project is to assess the scientific and economic utility of MetaMap® Tox, a platform that uses metabolite patterns of rat plasma for early recognition of toxicity for new drugs. Nine leading biopharmaceutical companies, whose names are undisclosed, will participate in the collaborative evaluation of MetaMap® Tox.

"The MetaMap® Tox solution is an exciting new tool to assess the safety of a compound in the development phase. This project supports CHA's mission of streamlining the research and development process," said Eric Glazer, Managing Director, DSEC.

"MetaMap® Tox offers the unique possibility to monitor systemic toxicological response of rats to new chemical entities based on < 100 established specific metabolic patterns indicative for toxicological modes of action. The benefit is to better and earlier identify the potential safety risks for a test compound and help guiding steps to mitigate risk in early drug development," said Tim Boelke, Managing Director, Metanomics Health GmbH.

Boelke continued, "We are therefore excited that Metanomics Health is one of a select few technology providers invited to participate in the DSEC Technology Evaluation Consortium."

Advertisement